Background Polycystic ovary syndrome (PCOS) is the most common endocrinopathy among
reproductive age women. Although its cardinal manifestations include hyperandrogenism …

More than 1 out of 10 women worldwide are diagnosed with polycystic ovary syndrome
(PCOS), the leading cause of female reproductive and metabolic dysfunction. Despite its …

Polycystic ovary syndrome (PCOS) has multiple etiologies including ovarian and adrenal
hyperandrogenism, neuro-endocrine and hypothalamic-pituitary dysfunction, and disorders …

Polycystic ovary syndrome (PCOS) is a heterogeneous and complex disorder that has both
adverse reproductive and metabolic implications for affected women. However, there is …

Polycystic ovary syndrome (PCOS) is now recognized as an important metabolic as well as
reproductive disorder conferring substantially increased risk for type 2 diabetes. Affected …

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in females, with
a high prevalence. The etiology of this heterogeneous condition remains obscure, and its …

Polycystic ovary syndrome (PCOS) is a prevalent hormonal disorder of premenopausal
women worldwide and is characterized by reproductive, endocrine, and metabolic …

Myo-inositol (MI) supplementation in women with polycystic ovary syndrome (PCOS) has
been evaluated over the last years. Many hormonal and reproductive impairments …

Polycystic ovary syndrome (PCOS) is a very common endocrine disorder characterized by
chronic anovulation, clinical and/or biochemical hyperandrogenism, and/or polycystic …

Epidemiological studies have reported an increased risk of cancer in people with type 2
diabetes (T2DM) and obesity, related in part to hyperinsulinemia, secondary to insulin …